How GLP-1s actually improve fertility
The fertility boost from semaglutide and tirzepatide isn't magic. It's weight loss reshaping your hormones. When you lose 10% or more of your body weight, something measurable happens: irregular periods become regular. Ovulation restarts. Insulin sensitivity improves.
This matters because irregular periods are often a sign of insulin resistance or PCOS, both of which tanked fertility. The SELECT trial showed 44% of semaglutide users lost more than 10% body weight, and 11% lost more than 20%. That's the population seeing menstrual restoration and improved fertility outcomes in the observational data.
A 2025 review in Annals of Medicine and Surgery found that GLP-1 receptor agonists improve insulin resistance and hyperandrogenism (elevated androgens that disrupt ovulation), leading to restored menstrual regularity and increased ovulation rates. The mechanism is weight loss, not the drug itself — but the drug makes the weight loss reliable enough that fertility improves as a secondary outcome.
The birth control problem (and it's specific)
Here's what most articles skip: tirzepatide slows gastric emptying. This means oral contraceptives pass through your stomach more slowly, reducing absorption. Semaglutide doesn't do this. Only tirzepatide.
The FDA updated prescribing information for tirzepatide to recommend switching to non-oral birth control or adding a backup barrier method for 4 weeks after starting and for 4 weeks after each dose increase. This is not a minor detail if you're relying on the pill.
If you're on tirzepatide and using oral contraceptives as your only birth control, speak to your doctor about switching to an IUD, implant, shot, or ring, or adding condoms. This isn't a reason to stop tirzepatide if it's helping. It's a reason to adjust your contraception strategy.
Timing: when to stop before trying to conceive
Both drugs have long half-lives, so they stay in your system longer than you'd expect. Semaglutide needs to be discontinued at least 35 days before you plan to conceive. Tirzepatide needs 25–35 days. Liraglutide only needs 3 days.
Why? These drugs suppress appetite and slow gastric emptying. During early pregnancy, you need normal appetite and normal digestion to support the metabolic demands of pregnancy. Stopping these medications 4–5 weeks early gives your body time to recalibrate.
If you're planning pregnancy within the next 6 months and you're on a GLP-1, talk to your doctor now about the discontinuation timeline. Don't wait until you've missed a period. Knowing the specific drug you're on (semaglutide vs. tirzepatide) lets your doctor plan the stopping date correctly.
What about early pregnancy exposure?
This is the reassuring part. Dao et al. (2024) conducted a prospective cohort study of 168 pregnancies with first-trimester exposure to GLP-1 medications. The finding: no increased risk of congenital anomalies or pregnancy loss. That doesn't mean it's harmless at every dose, but it does mean accidental early pregnancy exposure while on these drugs doesn't carry the teratogenic risk many women fear.
Real-world data is still limited, and larger ongoing studies matter. But the current evidence suggests that if you become pregnant while still taking a GLP-1, the outcome risk is not elevated compared to pregnancies without exposure.
What to tell your doctor
- "I'm planning pregnancy within the next [timeframe]. Which GLP-1 am I on, and when should I stop?" (Let your doctor look it up — semaglutide vs. tirzepatide changes the answer.)
- "If I'm on tirzepatide, do I need to switch my birth control method?" (The answer is yes, unless you add barrier methods.)
- "What should my fertility expectations be at my current weight vs. after weight loss on this drug?" (Your doctor can give realistic timeline.)
When to speak to your fertility specialist
If you've been trying to conceive for more than 12 months (or 6 months if you're over 35), GLP-1 use doesn't change when you should seek help. But mention to your fertility doctor that you're on or recently stopped a GLP-1. They'll factor in recent weight loss when assessing your hormone levels and ovulation status, as these can shift rapidly during active weight loss.
References
- GLP-1 receptor agonists and preconception planning: bridging the gap between obesity treatment and reproductive safety. Annals of Medicine and Surgery. 2025. Full text
- Semaglutide and human reproduction: mechanisms of action and clinical implications. PMC. 2024;12333279. PMC12333279
- Dao R, et al. Inadvertent first-trimester exposure to GLP-1 receptor agonists and pregnancy outcomes. Fertility and Sterility. 2024. Prospective cohort of 168 pregnancies.
- SELECT Trial. Semaglutide (Wegovy) for weight loss in adults with overweight or obesity. Weight loss outcomes: 44% >10%, 11% >20%. 2023–2024.
- FDA Prescribing Information: Mounjaro (tirzepatide) and Zepbound. Updated contraceptive guidance on oral contraceptive absorption. 2024.